Literature DB >> 24785373

MiR-224 expression increases radiation sensitivity of glioblastoma cells.

Shailendra Upraity1, Sadaf Kazi1, Vijay Padul1, Neelam Vishwanath Shirsat2.   

Abstract

Glioblastoma (GBM) is the most common and highly aggressive primary malignant brain tumor. The intrinsic resistance of this brain tumor limits the efficacy of administered treatment like radiation therapy. In the present study, effect of miR-224 expression on growth characteristics of established GBM cell lines was analyzed. MiR-224 expression in the cell lines as well as in primary GBM tumor tissues was found to be low. Exogenous transient expression of miR-224 using either synthetic mimics or stable inducible expression using doxycycline inducible lentiviral vector carrying miR-224 gene, was found to bring about 30-55% reduction in clonogenic potential of U87 MG cells. MiR-224 expression reduced clonogenic potential of U87 MG cells by 85-90% on irradiation at a dose of 6Gy, a dose that brought about 50% reduction in clonogenic potential in the absence of miR-224 expression. MiR-224 expression in glioblastoma cells resulted in 55-65% reduction in the expression levels of API5 gene, a known target of miR-224. Further, siRNA mediated down-regulation of API5 was also found to have radiation sensitizing effect on glioblastoma cell lines. Analysis of the Cancer Genome Atlas data showed lower miR-224 expression levels in male GBM patients to correlate with poorer survival. Higher expression levels of miR-224 target API5 also showed significant correlation with poorer survival of GBM patients. Up-regulation of miR-224 or down-regulation of its target API5 in combination with radiation therapy, therefore appear as promising options for the treatment of glioblastoma, which is refractory to the existing treatment strategies.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  API5; Glioblastoma; MiR-224; Radiation sensitivity

Mesh:

Substances:

Year:  2014        PMID: 24785373     DOI: 10.1016/j.bbrc.2014.04.095

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  8 in total

1.  MicroRNA-590-3p enhances the radioresistance in glioblastoma cells by targeting LRIG1.

Authors:  Long Chen; Wenhua Wang; Shengqiang Zhu; Xuegang Jin; Jian Wang; Jianfang Zhu; Youxin Zhou
Journal:  Exp Ther Med       Date:  2017-06-28       Impact factor: 2.447

2.  Circ_0060055 Promotes the Growth, Invasion, and Radioresistance of Glioblastoma by Targeting MiR-197-3p/API5 Axis.

Authors:  Jinjin Yuan; Zongwen Liu; Junqi Liu; Ruitai Fan
Journal:  Neurotox Res       Date:  2022-07-18       Impact factor: 3.978

Review 3.  MicroRNA-224: as a potential target for miR-based therapy of cancer.

Authors:  Wei Chen; Xue-Mei Fan; Ling Mao; Jun-Ying Zhang; Jian Li; Jian-Zhong Wu; Jin-Hai Tang
Journal:  Tumour Biol       Date:  2015-08-08

4.  Decreased microRNA-224 and its clinical significance in non-small cell lung cancer patients.

Authors:  Dan Zhu; Hui Chen; Xiguang Yang; Weisong Chen; Linying Wang; Jilin Xu; Long Yu
Journal:  Diagn Pathol       Date:  2014-11-19       Impact factor: 2.644

5.  CircPCMTD1 Acts as the Sponge of miR-224-5p to Promote Glioma Progression.

Authors:  Si-Qi Zheng; Yue Qi; Jun Wu; Fen-Li Zhou; Hao Yu; Lu Li; Bo Yu; Xiao-Fan Chen; Wei Zhang
Journal:  Front Oncol       Date:  2019-05-22       Impact factor: 6.244

Review 6.  MicroRNAs at the Crossroad of the Dichotomic Pathway Cell Death vs. Stemness in Neural Somatic and Cancer Stem Cells: Implications and Therapeutic Strategies.

Authors:  Andrea Diana; Giuseppe Gaido; Cristina Maxia; Daniela Murtas
Journal:  Int J Mol Sci       Date:  2020-12-17       Impact factor: 5.923

7.  Circulating microRNA profiles in plasma: identification of miR-224 as a novel diagnostic biomarker in hepatocellular carcinoma independent of hepatic function.

Authors:  Wataru Okajima; Shuhei Komatsu; Daisuke Ichikawa; Mahito Miyamae; Tsutomu Kawaguchi; Shoji Hirajima; Takuma Ohashi; Taisuke Imamura; Jun Kiuchi; Tomohiro Arita; Hirotaka Konishi; Atsushi Shiozaki; Ryo Moriumura; Hisashi Ikoma; Kazuma Okamoto; Hiroki Taniguchi; Yoshito Itoh; Eigo Otsuji
Journal:  Oncotarget       Date:  2016-08-16

8.  Prognostic Impact of miR-224 and RAS Mutations in Medullary Thyroid Carcinoma.

Authors:  Elisabetta Cavedon; Susi Barollo; Loris Bertazza; Gianmaria Pennelli; Francesca Galuppini; Sara Watutantrige-Fernando; Simona Censi; Maurizio Iacobone; Clara Benna; Federica Vianello; Stefania Zovato; Davide Nacamulli; Caterina Mian
Journal:  Int J Endocrinol       Date:  2017-06-06       Impact factor: 3.257

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.